Comparison of Propofol and Sevoflurane as a Primary Anesthetic for Cardiac Ablation of Atrial Fibrillation.

Overview

Comparison of propofol and sevoflurane as a primary anesthetic for cardiac ablation of atrial fibrillation

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Single (Outcomes Assessor)
  • Study Primary Completion Date: June 30, 2023

Detailed Description

A side effect of some volatile anesthetics, such as isoflurane and desflurane, is enhanced automaticity, accounting for secondary atrial pacemakers. Volatile anesthetics also have varying effects on the AV node and His-Pukinje system. These agents also prolong the QT interval and, for this reason, volatile anesthetics as a group have at times been avoided for atrial fibrillation ablation due to the fear that they may affect the efficacy of the ablation and increase recurrence. However, sevoflurane does not have the effects shown for other volatile anesthetics cardiac conduction. At this point there has not been a study comparing propofol, a non volatile anesthetic typically used in these cases, to sevoflurane, a volatile anesthetic, to determine if volatile anesthetics should be avoided during these procedures. This study will challenge the existing belief that sevoflurane increases the length of time to ablate atrial fibrillation and also decreases the efficacy of the ablation.

Interventions

  • Drug: propofol
    • Participant receives propofol as anesthetic for cardiac ablation.
  • Drug: sevoflurane
    • Participant receives sevoflurane as anesthetic for cardiac ablations.

Arms, Groups and Cohorts

  • Active Comparator: propofol
    • Participants receiving propofol as anesthetic for cardiac ablation.
  • Active Comparator: sevoflurane
    • Participants receiving sevoflurane as anesthetic for cardiac ablation.

Clinical Trial Outcome Measures

Primary Measures

  • procedure duration
    • Time Frame: 1 day
    • The duration of the procedure in minutes.

Participating in This Clinical Trial

Inclusion Criteria

  • have paroxysmal atrial fibrillation – undergoing their first ablation. Exclusion Criteria:

  • none

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 80 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Medical University of South Carolina
  • Provider of Information About this Clinical Study
    • Principal Investigator: George Guldan, Principal Investigator – Medical University of South Carolina
  • Overall Official(s)
    • George J Guldan, M.D., Principal Investigator, Medical University of South Carolina

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.